2016 International Congress

Thursday, June 23, 2016

12:00pm-1:30pm

Structural organization of the brain connectome in patients with psychogenic dystonia

S. Basaia, F. Agosta, A. Tomic, E. Sarasso, M. Svetel, S. Galantucci, V.S. Kostic, M. Filippi (Milano, Italy)

Dystonia  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Subcutaneous apomorphine reduces OFF time and dyskinesias and improves quality of life in Parkinson’s disease (PD) – 5-year follow-up of patients in Greece

G.A. Tagaris, A. Skafida, D. Athanasopoulos, E. Trachani, S. Tsiara (Athens, Greece)

Parkinson's disease: Clinical trials, pharmacology and treatment  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Subthalamic deep brain stimulation vs. intraduodenal levodopa infusion: A long-term retrospective comparative study

A. Merola, A.J. Espay, A. Romagnolo, A. Bernardini, M. Rosso, K.J. Espay, L. Rizzi, M. Zibetti, M. Lanotte, L. Lopiano (Torino, Italy)

Parkinson's disease: Clinical trials, pharmacology and treatment  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Subtle sensory abnormalities in patients with segmental and cervical dystonia detected by quantitative sensory testing

L. Paracka, F. Wegner, C. Blahak, M. Abdallat, M. Karst, D. Dressler, J.K. Krauss (Hannover, Germany)

Dystonia  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Successful treatment of movement disorders after resection of midbrain cavernous malformations: Report of two cases

A. Smolanka, V. Smolanka, K. Karpinska, M. Dovhanych, T. Havryliv (Uzhhorod, Ukraine)

Other  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Suggested criteria for patient selection for therapy with carbidopa/levodopa enteral suspension (CLES)

R.L. Rodriguez, T. Green, F. Rossi, A. Khaku, J. Slevin (Orlando, FL, USA)

Parkinson's disease: Clinical trials, pharmacology and treatment  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Supplement use in PD is associated with delayed initiation of dopaminergic therapy

L. Chahine, S. Xie, K. Smith, C. Scordia, R. Purri, C. Linder, J. Duda, N. Dahodwala (Philadelphia, PA, USA)

Parkinson's disease: Clinical trials, pharmacology and treatment  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Swallowing difficulties in patients with Parkinson’s disease and Parkinsonian syndromes

Y.O. Trufanov (Kyiv, Ukraine)

Parkinson's disease: Clinical trials, pharmacology and treatment  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Switching double-blind opicapone, entacapone or placebo to open-label opicapone: Efficacy results of the 1-year extension of study BIPARK I

J. Ferreira, A. Lees, E. Tolosa, W. Poewe, A. Santos, N. Lopes, J.F. Rocha, P. Soares-da-Silva (Lisbon, Portugal)

Parkinsons's Disease: Clinical Trials I

12:00pm-1:30pm

Symptoms of dystonia in a mouse with mutation in Lamb1

K.J. Sweadner, Y.B. Liu, A. Tewari, J. Salameh, A. Brashear, L.J. Ozelius, K. Khodakhah (Boston, MA, USA)

Dystonia  ·  Exhibit Hall located in Hall B, Level 2